Focused on the development of novel targeted medicines to validated anti-cancer and fibrosis targets in areas of unmet need

Redx Pharma uses its proven drug discovery expertise to generate development candidates that it will take into the clinic. The company’s product development strategy has three interrelated components:

Cancer: Progress RXC004, our lead clinical asset in Phase 1

  • Progress oral porcupine inhibitor RXC004 in ongoing Phase 1 clinical trial in patients with advanced cancer to establish safety, tolerability and optimal treatment dose
  • Investigate RXC004 as targeted monotherapy treatment for cancer with high unmet need (metastatic colorectal, pancreatic and biliary cancer) and in combination with anti-PD-(L)1 checkpoint inhibitors

Fibrosis: Take RXC007 into clinic

  • Take selective ROCK2 inhibitor RXC007 into Phase 1 clinical trial in 2021
  • RXC007 holds potential to address multiple fibrotic diseases with high unmet need, including idiopathic pulmonary fibrosis (IPF), non-alcoholic steatohepatitis (NASH) and diabetic nephropathy (DN)

Research: Next generation therapies

  • Pan-RAF inhibitor research programme with Jazz Pharmaceuticals
  • Progress exciting anti-fibrotic research programmes into development
    • Porcupine Inhibitor RXC006: Idiopathic pulmonary fibrosis (IPF)
    • GI-targeted ROCK Inhibitor: Crohn’s disease-associated fibrosis
  • Preclinical research programmes to generate novel development compounds through Redx’s demonstrated strength in medicinal chemistry and translational biology